Health
LegoChem Biosciences and Iksuda Therapeutics expand License Agreement for development of antibody-drug conjugates – News-Medical.net
Iksuda Therapeutics today announced that it has expanded its research collaboration and License Agreement with LegoChem Biosciences,…
Iksuda Therapeutics, the developer of a new generation of antibody drug conjugates (ADCs) with raised therapeutic index, today announced that it has expanded its research collaboration and License Agreement with LegoChem Biosciences, Inc. (“LCB”) to explore…
Continue Reading
-
Noosa News16 hours agoBrisbane vs Collingwood live blog: Richmond selects Noah Balta as unbeaten Lions prepare for Magpies test
-
General15 hours agoNT Coalition candidate Lisa Siebert diverges from Jacinta Nampijinpa Price on royal commission call
-
General23 hours agoMinecraft mayhem: ‘Chicken jockey’ chaos reaches Australian cinemas
-
General17 hours agoCanberra man named as doctor accused of rape after suppression order lifted